基线循环肿瘤DNA用于初治转移性结直肠癌患者的个体化预后判断:AGEO前瞻性研究
该前瞻性研究纳入412例未接受化疗的转移性结直肠癌患者,基线血浆ctDNA经NGS和甲基化数字PCR集中检测。ctDNA突变等位基因频率(MAF)最佳截断值为20%,MAF≥20%与<20%患者中位OS分别为16.0个月和35.8个月(HR=0.40,95%CI 0.31-0.51,P<0.0001)。ctDNA MAF 20%的独立预后价值在RAS/BRAF状态或转移灶可切除性定义的亚组中均得到证实。
要点
- 基线ctDNA MAF截断值20%可区分初治mCRC患者预后,≥20%者中位OS为16.0个月,<20%者为35.8个月。
- ctDNA MAF 20%的独立预后价值在RAS/BRAF状态或转移灶可切除性亚组中均得到证实。
- 联合ctDNA MAF与癌胚抗原水平可定义三个预后组,中位OS分别为14.2、21.1和46.4个月(P<0.0001)。
核心结论
- ctDNA MAF截断值20%可改善初治mCRC患者的预后判断,未来可能有助于个体化治疗决策并作为临床试验的分层因素。
研究设计与样本
- AGEO前瞻性研究,2015年7月至2016年12月纳入412例未接受化疗的转移性结直肠癌患者,诊断时采集血浆样本,经NGS和甲基化数字PCR集中分析。
- 收集基线患者及疾病特征、治疗方案和二次手术信息,采用限制性立方样条法确定ctDNA MAF最佳截断值,用Cox模型评估总生存期预后价值。
- 试验注册号:Clinicaltrials.gov,NCT02502656。
主要发现
- 83例患者(20%)ctDNA检测不到。
- 在全研究人群中,ctDNA是OS的独立预后标志物。
- ctDNA MAF最佳截断值为20%,MAF≥20%与<20%患者中位OS分别为16.0个月和35.8个月(HR=0.40;95%CI 0.31-0.51;P<0.0001)。
- ctDNA MAF 20%的独立预后价值在RAS/BRAF状态或转移灶可切除性定义的亚组中均得到证实。
- 联合ctDNA MAF与癌胚抗原水平定义三个预后组,中位OS分别为14.2、21.1和46.4个月(P<0.0001)。
关键数值与推荐
- ctDNA MAF最佳截断值为20%,MAF≥20%与<20%患者中位OS分别为16.0个月和35.8个月(HR=0.40;95%CI 0.31-0.51;P<0.0001)。
- 联合ctDNA MAF与癌胚抗原水平定义的三个预后组中位OS分别为14.2、21.1和46.4个月(P<0.0001)。
临床怎么用
- 作者认为,ctDNA MAF截断值20%可改善初治mCRC患者的预后判断,未来可能有助于个体化治疗决策并作为临床试验的分层因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal cancer (mCRC) patients. However, few studies have compared ctDNA with the usual prognostic factors, and no ctDNA cut-off has been proposed for daily use in clinical practice. PATIENTS AND METHODS: Chemotherapy-naive patients with mCRC were prospectively included. Plasma samples were collected at diagnosis and analysed centrally by both NGS and methylation digital PCR. Baseline patient and disease characteristics, treatment regimens, and secondary surgeries were collected. The restricted cubic spline method was used to define the optimal cut-off of ctDNA mutated allelic frequency (MAF). Prognostic values were assessed on overall survival (OS) using Cox models. RESULTS: From July 2015 to December 2016, 412 patients were included. ctDNA was undetectable in 83 patients (20%). ctDNA was an independent prognostic marker for OS considering the whole study population. The optimal cut-off for ctDNA MAF was 20% with median OS of 16.0 and 35.8 months for patients with MAF ≥20% and<20%, respectively (hazard ratio = 0.40; 95% confidence intervals: 0.31-0.51; P < 0.0001). The independent prognostic value of ctDNA MAF at 20% was confirmed in subgroups defined by RAS/BRAF status or resectability of metastases. Combining ctDNA MAF and carcinoembryonic antigen levels allowed us to define three different prognostic groups with median OS of 14.2, 21.1, and 46.4 months (P < 0.0001). CONCLUSION: ctDNA with a MAF cut-off of 20% improves prognostication of chemotherapy-naïve mCRC patients and may be useful in the future for individualised therapeutic decisions and as a stratification factor in clinical trials. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02502656.
引用
- Bachet JB, Laurent-Puig P, Meurisse A, et al. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study. Eur J Cancer. 2023. PMID: 37390800. doi:10.1016/j.ejca.2023.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。